JOURNAL ARTICLE

Prognostic impact of prostate‐specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node‐positive prostate cancer.

  • Published In: Journal of Medical Imaging & Radiation Oncology, 2024, v. 68, n. 6. P. 721 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Leow, Boon Yang Jerome; Eade, Thomas; Hruby, George; Lieng, Hester; Hsiao, Edward; Brown, Chris; Kneebone, Andrew 3 of 3

Abstract

Introduction: In the current American Joint Committee on Cancer staging system, patients with pelvic nodal metastases are considered stage IV prostate cancer. This study aims to investigate whether men with prostate‐specific membrane antigen positron emission tomography (PSMA PET)‐detected pelvic node‐positive prostate cancer at diagnosis have a better outcome compared to men with node‐positive disease identified on conventional imaging. Methods: This is a retrospective cohort study comparing the outcomes of men with node‐positive prostate cancer and disease confined to the pelvis, staged with conventional versus PSMA PET imaging. Men had to be treated definitively with a combination of androgen deprivation therapy and radiation treatment to the prostate and pelvic lymph nodes. Kaplan–Meier and Cox regression analysis was used to compare biochemical failure‐free survival (BFFS) and overall survival (OS). Results: Seventy‐six men with nodal metastases confined to the pelvis were identified. Fifty‐one were detected with PSMA PET while 25 were staged with conventional imaging. PSMA PET staged patients had a lower proportion of Gleason 8–10 disease (78% vs. 96%) as well as a lower median prostate‐specific antigen (11 ng/mL vs. 26 ng/mL). BFFS at 4 years was 72% with PSMA PET‐detected node‐positive disease vs. 38% with conventionally detected node‐positive disease. Four‐year OS was 93% with PSMA PET staged patients vs. 76% with conventionally staged patients. On multivariate analysis, the PSMA PET staged group was associated with improved BFFS (Adjusted HR = 3.00, 95% CI 1.43, 6.29, P = 0.004) and OS (Adjusted HR = 5.81, 95% CI 1.43, 23.7, P = 0.007). Conclusion: Men with PSMA PET‐detected node‐positive prostate cancer confined to the pelvis have significantly better biochemical control and survival compared to those with node‐positive pelvic disease identified through conventional staging. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Journal of Medical Imaging & Radiation Oncology. 2024/09, Vol. 68, Issue 6, p721
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2024
  • ISSN:1754-9477
  • DOI:10.1111/1754-9485.13655
  • Accession Number:180170784
  • Copyright Statement:Copyright of Journal of Medical Imaging & Radiation Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.